IP Library Granted Patent US 11,213,498
Granted Patent B2
US 11,213,498 · App. 16/424,274 · Granted Jan 4, 2022

Aqueous formulation comprising paracetamol and ibuprofen

Inventor: Thomas Jacobsen (Windhof, LU)
Assignee: Hyloris Pharmaceuticals S.A.
A61K31/192A61J1/10A61J1/2093A61K9/0019A61K9/08A61K31/167A61K47/20A61K47/26A61M5/1407A61M5/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,213,498
App. No.
16/424,274
Granted
Jan 4, 2022
Kind
B2
Abstract

An aqueous ibuprofen and paracetamol composition has a pH 6.3-7.3. The composition can be used as a medicament, especially for the treatment of pain and/or inflammation. The composition can be formulated for intravenous injection.

Claims (8)

1. An aqueous composition comprising 2.8-3.2 mg/ml ibuprofen and 9.8-10.2 mg/ml paracetamol and having a pH at the time of preparation (t 0 ) that is between 6.3 and 6.8, inclusive, wherein the ibuprofen and the paracetamol remain in solution for at least 6 months at 25±2° C. and 40±5% relative humidity.

2. The aqueous composition of claim 1 , wherein after one year of storage at 25±2° C. and 40±5% relative humidity, the level of 4-aminophenol in the composition is below 0.05% and the level of 4-nitrophenol in the composition is below 0.05%.

3. The aqueous composition of claim 1 , wherein the pH six months after the time of preparation is no higher than 7.3.

4. The aqueous composition of claim 1 , comprising 3 mg/ml ibuprofen and 10 mg/ml paracetamol.

5. The aqueous composition of claim 1 , further comprising an isotonic agent.

6. The aqueous composition of claim 1 , wherein the isotonic agent is mannitol.

7. The aqueous composition of claim 1 , further comprising cysteine.

8. The composition of claim 1 , having a dissolved oxygen content below 2 ppm.

Assignments (3)
CHANGE OF NAME Recorded Aug 5, 2021
From: EVERBRIGHT S.A.R.L.
To: HYLORIS PHARMACEUTICALS SA
Reel/Frame 057091/0054 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 055504 FRAME: 0521. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 12, 2021
From: JACOBSEN, THOMAS
To: EVERBRIGHT S.A.R.L.
Reel/Frame 056832/0743 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2021
From: JACOBSEN, THOMAS
To: EVERBRIGHT PHARMACEUTICALS S.A.R.L.
Reel/Frame 055504/0521 →
Priority Claims (1)
WO PCT/EP2014/065544 · Jul 18, 2014 · international
Continuity (2)
Division 15326958
Related Publication 20190343785A1 · Nov 14, 2019